Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Key Insights on Gilead Sciences – A Stock Overview

Shares of Health Care sector company Gilead Sciences moved -1.3% today, and are now trading at a price of $134.43. The Large-Cap stock's daily volume was 11,367,563 compared to its average volume of 5,937,687. The S&P 500 index returned a 0.0% performance.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company is based in Foster City and has 17,000 full time employees. Its market capitalization is $166,904,233,984. Gilead Sciences currently offers its equity investors a dividend that yields 2.3% per year.

29 analysts are following Gilead Sciences and have set target prices ranging from $122.0 to $180.0 per share. On average, they have given the company a rating of buy. At today's prices, GILD is trading -14.82% away from its average analyst target price of $157.83 per share.

Over the last year, GILD's share price has increased by 23.7%, which represents a difference of -4.2% when compared to the S&P 500. The stock's 52 week high is $157.29 per share whereas its 52 week low is $104.46. With average free cash flows of $8.97 Billion that have been growing at an average rate of 0.6% over the last 5 years, Gilead Sciences is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2025 10,019,000 563,000 9,456,000 -8.24
2024 10,828,000 523,000 10,305,000 38.86
2023 8,006,000 585,000 7,421,000 -11.06
2022 9,072,000 728,000 8,344,000 -22.78
2021 11,384,000 579,000 10,805,000 43.72
2020 8,168,000 650,000 7,518,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS